AI Verdict
PBHC has stronger fundamentals based on our AI analysis.
PCSA vs PBHC Fundamental Comparison
| Metric | PCSA | PBHC |
|---|---|---|
| Revenue | $0.0 | $76.7M |
| Net Income | $-13.6M | $-1.9M |
| Net Margin | N/A | -2.5% |
| ROE | -243.2% | -1.6% |
| ROA | -173.6% | -0.1% |
| Current Ratio | 2.54x | N/A |
| Debt/Equity | 0.00x | 0.11x |
| EPS | $-10.36 | $0.47 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
PCSA vs PBHC: Frequently Asked Questions
Is PCSA or PBHC a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), PBHC has stronger fundamentals. PCSA is rated STRONG SELL (87% confidence) while PBHC is rated SELL (45% confidence). This is not investment advice.
How does PCSA compare to PBHC fundamentally?
Processa Pharmaceuticals, Inc. has ROE of -243.2% vs Pathfinder Bancorp, Inc.'s -1.6%. Net margins are N/A vs -2.5% respectively.
Which stock pays higher dividends, PCSA or PBHC?
PCSA has a dividend yield of N/A or no dividend while PBHC has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in PCSA or PBHC for long term?
For long-term investing, consider that PCSA has STRONG SELL rating with 87% confidence, while PBHC has SELL rating with 45% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about PCSA vs PBHC?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For PCSA vs PBHC, the AI consensus favors PBHC based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.